ChiCTR2400094638 版本V1.0 版本创建时间2024/12/25 15:43:47 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400094638 

最近更新日期:

Date of Last Refreshed on:

2024-12-25 15:43:40 

注册时间:

Date of Registration:

2024-12-25 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于AI的斜视筛查平台在婴幼儿斜视中的应用

Public title:

Application of an Artificial Intelligence Strabismus Screening Platform in Infantile Strabismus

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于AI的斜视筛查平台在婴幼儿斜视中的应用

Scientific title:

Application of an Artificial Intelligence Strabismus Screening Platform in Infantile Strabismus

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

江明明 

研究负责人:

江明明 

Applicant:

Jiang Mingming 

Study leader:

Jiang Mingming 

申请注册联系人电话:

Applicant telephone:

+86 131 6516 2961

研究负责人电话:

Study leader's
telephone:

+86 131 6516 2962

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jiangmingming90@126.com

研究负责人电子邮件:

Study leader's E-mail:

jiangmingming90@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省青岛市市南区燕儿岛路5号

研究负责人通讯地址:

山东省青岛市市南区燕儿岛路5号

Applicant address:

5 Yan'erdao Road, Shinan District, Qingdao, Shandong

Study leader's address:

5 Yan'erdao Road, Shinan District, Qingdao, Shandong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东第一医科大学附属青岛眼科医院

Applicant's institution:

Qingdao Eye Hospital of Shandong First Medical University

研究负责人所在单位:

山东第一医科大学附属青岛眼科医院

Affiliation of the Leader:

Qingdao Eye Hospital of Shandong First Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

青眼伦审(快)[2024]42号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山东第一医科大学附属青岛眼科医院伦理委员会

Name of the ethic committee:

Ethics Committee of Qingdao Eye Hospital of Shandong First Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-05-17 00:00:00

伦理委员会联系人:

周庆军

Contact Name of the ethic committee:

Zhou Qingjun

伦理委员会联系地址:

山东省青岛市市南区燕儿岛路5号

Contact Address of the ethic committee:

5 Yan'erdao Road, Shinan District, Qingdao, Shandong

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 532 8587 6380

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东第一医科大学附属青岛眼科医院

Primary sponsor:

Qingdao Eye Hospital of Shandong First Medical University

研究实施负责(组长)单位地址:

山东省青岛市市南区燕儿岛路5号

Primary sponsor's address:

5 Yan'erdao Road, Shinan District, Qingdao, Shandong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

青岛

Country:

China

Province:

Shandong

City:

Qingdao

单位(医院):

山东第一医科大学附属青岛眼科医院

具体地址:

山东省青岛市市南区燕儿岛路5号

Institution
hospital:

Qingdao Eye Hospital of Shandong First Medical University

Address:

5 Yan'erdao Road, Shinan District, Qingdao, Shandong

经费或物资来源:

自筹

Source(s) of funding:

Self-raised

研究疾病:

斜视  

Target disease:

Strabismus

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评估人工智能斜视筛查平台在婴幼儿斜视中的应用  

Objectives of Study:

Evaluating an Artificial Intelligence Strabismus Screening Platform in Infant Strabismus

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄:3岁以下儿童; 2. 怀疑或者存在眼位异常; 3. 患儿家属自愿签署知情同意书。

Inclusion criteria

1. Age: children under 3 years old; 2. suspicion or presence of abnormal eye position; 3. Voluntary informed consent signed by the child's family.

排除标准:

1. 合并严重眼睑发育异常、眼球萎缩或者严重角膜白斑患儿; 2. 家属拒绝参加检查; 3. 患儿全身情况不能完成本检查患儿。

Exclusion criteria:

1. children with combined severe eyelid developmental abnormalities, ocular atrophy, or severe corneal leukoplakia; 2. The family refuses to participate in the examination; 3. Children whose general condition prevents them from completing the examination.

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-01-01 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

人工智能斜视筛查组

样本量:

100

Group:

Artificial Intelligence Strabismus Screening Group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

对照组

样本量:

100

Group:

control group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

青岛 

Country:

China

Province:

Shandong

City:

Qingdao

单位(医院):

山东第一医科大学附属青岛眼科医院 

单位级别:

三甲 

Institution
hospital:

Qingdao Eye Hospital of Shandong First Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

视力

指标类型:

次要指标

Outcome:

Vision

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

屈光度

指标类型:

次要指标

Outcome:

Diopter

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼位照相

指标类型:

主要指标

Outcome:

Ophthalmoscopy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼位检查

指标类型:

主要指标

Outcome:

Eye position and eye movement

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

同视机

指标类型:

主要指标

Outcome:

Synoptic examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

三棱镜斜视度

指标类型:

主要指标

Outcome:

Prism examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼球运动

指标类型:

主要指标

Outcome:

Eye movement examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 3 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

none

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2026年12月31日之后,ResMan

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After December 31, 2026, ResMan

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病历记录表的方式采集数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic acquisition and management system.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-12-25 15:43:40